Off-Label Semaglutide Use for Lower BMI The FDA's official indication for semaglutide weight-loss medications requires a BMI of 30 kg/m or higher in most adults, or a BMI of 27 or above with at least one weight-related medical condition such as hypertension, type 2 diabetes, or cardiovascular disease
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats
In addition, weekly alcohol cravings dropped by about 40%, while there were also bigger reductions in heavy drinking over time compared to the placebo group
These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition.
Disclaimer: Compounded medications are not FDA-approved drug products